Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4021544 | 1.00 | ALDH1A1 (0.47) | ALDH1A1GAAKDM4EMAPTLMNA | |
| SCHEMBL4021537 | 1.00 | ALDH1A1 (0.47) | ALDH1A1GAAKDM4EMAPTLMNA | |
| SCHEMBL12172750 | 0.98 | ALDH1A1 (0.49) | ALDH1A1GAAKDM4EMAPTLMNA | |
| SCHEMBL1832185 | 0.90 | ALDH1A1 (0.52) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL1832187 | 0.90 | ALDH1A1 (0.52) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL22622465 | 0.87 | ALDH1A1 (0.48) | ALDH1A1MAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL21851237 | 0.79 | ALDH1A1 (0.50) | ALDH1A1GAAKDM4EMAPTLMNA | |
| SCHEMBL17672298 | 0.79 | ALDH1A1 (0.43) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| Maleic Acid SCHEMBL29790549 | 0.79 | ALDH1A1 (0.42) | ALDH1A1GAASMN1; SMN2TSHRTP53 | |
| SCHEMBL21872351 | 0.78 | ALDH1A1 (0.46) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230350305-A1 | MANUFACTURING METHOD FOR CURED SUBSTANCE, MANUFACTURING METHOD FOR LAMINATE, AND MANUFACTURING METHOD FOR SEMICONDUCTOR DEVICE, AND TREATMENT LIQUID | FUJIFILM CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230350305-A1 | MANUFACTURING METHOD FOR CURED SUBSTANCE, MANUFACTURING METHOD FOR LAMINATE, AND MANUFACTURING METHOD FOR SEMICONDUCTOR DEVICE, AND TREATMENT LIQUID | FUJIFILM CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230213858-A1 | MANUFACTURING METHOD FOR CURED SUBSTANCE, MANUFACTURING METHOD FOR LAMINATE, AND MANUFACTURING METHOD FOR SEMICONDUCTOR DEVICE | FUJIFILM CORPORATION (JP) | 2023-07-06 | — | — | US | disclosed |
| US-20230213858-A1 | MANUFACTURING METHOD FOR CURED SUBSTANCE, MANUFACTURING METHOD FOR LAMINATE, AND MANUFACTURING METHOD FOR SEMICONDUCTOR DEVICE | FUJIFILM CORPORATION (JP) | 2023-07-06 | — | — | US | disclosed |
| CN-111423396-B | sEH inhibitor, and preparation method and application thereof | 沈阳药科大学 | 2023-01-06 | — | — | CN | disclosed |
| CN-111423396-A | sEH inhibitor, and preparation method and application thereof | 沈阳药科大学 | 2020-07-17 | — | — | CN | disclosed |
| WO-2020054226-A1 | PHOTOSENSITIVE RESIN COMPOSITION, CURED FILM, LAMINATE, METHOD FOR PRODUCING CURED FILM, AND SEMICONDUCTOR DEVICE | 富士フイルム株式会社 | 2020-03-19 | — | — | WO | disclosed |
| EP-1091929-B1 | SECONDARY ASPARTIC ACID AMIDE ESTERS | MINNESOTA MINING & MFG (US) | 2004-06-02 | — | — | EP | disclosed |
| US-6573398-B2 | Such as (Z)-4-(tert-butylamino)-4-oxo-2-butenoic acid; protective coatings for use as two-part liquid pavement markings | 3M INNOVATIVE PROPERTIES COMPANY | 2003-06-03 | — | — | US | disclosed |
| US-20030004367-A1 | Secondary aspartic acid amide esters | 3M INNOVATIVE PROPERTIES COMPANY | 2003-01-02 | — | — | US | disclosed |
| US-6469199-B1 | USED IN COATINGS, E.G. POLYUREA COATINGS AND IN A LIQUID PAVEMENT MARKING COMPOSITION | 3M INNOVATIVE PROPERTIES COMPANY | 2002-10-22 | — | — | US | disclosed |
| EP-1091929-A2 | SECONDARY ASPARTIC ACID AMIDE ESTERS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001665-A2 | SECONDARY ASPARTIC ACID AMIDE ESTERS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 2000-01-13 | — | — | WO | disclosed |
| US-6005062-A | AND A POLYISOCYANATE COMBINED TO FORM A POLYUREA; TWO PART LIQUID PAVENT MARKING COMPOSITIONS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 1999-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004367-A1 | Secondary aspartic acid amide esters | PNISR, GLUL, NAAA | ALDH1A1 1489/4885GAA 1277/4885KDM4E 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.